Acetylcholine Receptor (AChR) Antibodies, Complete Profile

CPT: 83519(x3)
Print Share

Test Details


  • Acetylcholine Receptor Complete Antibody Profile
  • Myasthenia Gravis Evaluation Complete Profile

Test Includes

Acetylcholine receptor-binding antibody; acetylcholine receptor-blocking antibody; acetylcholine receptor-modulating antibody


Diagnose myasthenia gravis (MG); monitor response to treatment of myasthenia gravis


False positives can occur in patients with serum drawn within 48 hours of administration of general anesthesia and muscle relaxants. Antibodies to α-bungarotoxin may sometimes be found in patients treated with snake venom. Recently administered radioisotopes may interfere with the assay in unpredictable ways. Acetylcholine receptor autoantibodies are not typically found in congenital myasthenia gravis.

Results of this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.


AChR-binding assay and blocking antibody: radioimmunoassay (RIA); AChR-modulating antibody: cell culture based radioimmunoassay (RIA)

Additional Information

Myasthenia gravis is an autoimmune disorder manifested by muscle weakness caused by the loss or dysfunction of acetylcholine receptors (AChR) of skeletal muscle. Autoantibodies (binding, blocking, and/or modulating) to postsynaptic AChRs are detectable in the serum of 90% of patients with generalized MG and in 55% to 70% of patients with ocular myasthenia. These autoantibodies interfere with normal neuromuscular function, causing muscle weakness and fatigue. Receptor antibody levels tend to rise several weeks before symptoms increase in patients with established MG. Remission after thymectomy is associated with a progressive decline in antibody levels. Consequently, measurements of AChR antibodies can be used in monitoring disease progression as well as the effects of treatment. Modulating antibodies are responsible for the degradation of AChR at the muscle cell surface. Modulating antibodies bind to two receptor molecules on the cell surface and accelerate internalization, triggering endocytosis and degradation. The relative increase in this degradation rate closely corresponds to the disease severity.

Specimen Requirements




3 mL

Minimum Volume

1 mL (Note: This volume does not allow for repeat testing.)


Red-top tube or gel-barrier tube


Separate serum from cells within 45 minutes of collection. Send serum in plastic transport tube.

Storage Instructions

Refrigerate (cool pack)

Stability Requirements



Room temperature

7 days


14 days


14 days

Causes for Rejection

Improper labeling; gross microbial contamination; specimen contaminated with anticoagulants; chylous serum; plasma specimen

Clinical Information


Griesmann GE, Kryzer TJ, Lennon VA. Autoantibody profiles of myasthenia gravis and Lambert Eaton syndrome. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical Laboratory Immunology. 6th ed. Washington DC: ASM Press; 2002.
Hara H, Hayashi K, Ohta K, Itoh N, Nishitani H, Ohta M. Detection and characterization of blocking-type antiacetylcholine receptor antibodies in sera from patients with myasthenia gravis. Clin Chem. 1993 Oct; 39(10):2053-2057. 8403390
Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987; 505:526-538. 3479935
Howard JF Jr. Myasthenia gravis—A summary. Myasthenia Gravis Foundation of America, Carolinas Chapter Newsletter, November, 1997.
Lyons BW, Wu LL, Astill ME, Wu JT. Development of an assay for modulating antiacetylcholine receptor autoantibodies using human rhabdomyosarcoma cell line. J Clin Lab Anal. 1998; 12(5):315-319. 9773965
Palace J, Vincent A, Beeson D. Myasthenia gravis: Diagnostic and management dilemmas. Curr Opin Neurol. 2001 Oct; 14(5):583-589. 11562569
Wu JT, Astill M, Lloyd C, Salmon VC. Rhabdomyosarcoma cell line can be used for the isolation of soluble acetylcholine receptor for assaying blocking and modulating antibodies. J Clin Lab Anal. 1993; 7(1):11-18. 8426270


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
086007 Acetylcholine Receptor Ab, All 085904 AChR Binding Abs, Serum nmol/L 11034-6
086007 Acetylcholine Receptor Ab, All 085927 AChR Blocking Abs, Serum % 11561-8
086007 Acetylcholine Receptor Ab, All 085934 AChR Modulating Ab % 30192-9

For Providers

Please login to order a test.


© 2019  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at